Drugs / Influenza Monovalent Whole virus (H5N1) adjuvanted vaccine
Influenza Monovalent Whole virus (H5N1) adjuvanted vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00309647 | Mar → Nov 2006 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Influenza Monovalent Whole virus (H5N1) adjuvanted vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00309647 ↗ |
| Modality | Vaccine | “candidate pandemic H5N1 vaccine formulated from Whole Virus” NCT00309647 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT00309647 ↗ |